Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology pioneer developing next-generation immuno-oncology therapies using its proprietary INTASYL® RNAi platform. This page provides centralized access to official press releases, clinical trial updates, and strategic partnership announcements related to PHIO's innovative approach to enhancing immune cell function against cancer.
Investors and researchers will find timely updates on PHIO's progress in silencing immune checkpoint targets like PD-1 and TIGIT through its self-delivering siRNA technology. The resource covers key developments including clinical trial milestones, collaborative research findings, and regulatory advancements for therapies like lead candidate PH-762.
Content spans multiple categories essential for tracking biopharmaceutical innovation: clinical trial results, research collaborations with institutions like Gustave Roussy, intellectual property updates, and technology licensing agreements. Each update is sourced directly from company disclosures to ensure reliability.
Bookmark this page for streamlined monitoring of PHIO's advancements in RNAi-based cancer therapeutics. Check regularly for new developments in their mission to overcome tumor-induced immunosuppression through precision gene silencing.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced a registered direct offering of 240,000 shares of common stock priced at $2.00 per share, expected to raise $0.48 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules. Additionally, the company will issue unregistered warrants to purchase up to 240,000 shares with an exercise price of $2.00 per share, exercisable upon issuance and expiring in five years. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around December 24, 2024, with proceeds intended for working capital and general corporate purposes.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $1.15 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 437,192 shares of common stock at $2.635 per share, along with unregistered warrants to purchase an equal number of shares at $2.51 per share in a concurrent private placement. The warrants will be exercisable upon issuance and expire after five years.
H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is expected to close around December 20, 2024. Phio plans to use the net proceeds for working capital and general corporate purposes. The common stock offering is made under an effective S-3 shelf registration, while the warrants are issued through a private placement under Section 4(a)(2) of the Securities Act.
Phio Pharmaceuticals (NASDAQ: PHIO) announced positive results from the second cohort of its Phase 1b clinical trial evaluating PH-762 for treating various skin cancers. The Safety Monitoring Committee (SMC) recommended proceeding to the third dose cohort following encouraging safety data. The second cohort, comprising 4 patients with cutaneous squamous cell carcinoma, showed promising results with the first two patients achieving complete response (100% tumor clearance) and partial response (90% clearance) at Day 36. The intratumoral injections were well-tolerated with no dose-limiting toxicities or serious adverse events reported.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the publication of their research on PH-762, their INTASYL® siRNA compound, in Frontiers in Immunology. The article presents preclinical proof-of-concept data for PH-762, designed to silence PD-1 for cancer treatment. Recent Phase 1b clinical trial data showed promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance) in cutaneous squamous cell carcinoma treatment.
Phio Pharmaceuticals (NASDAQ: PHIO) has been nominated as a finalist for the Technology Disruptor of the Year award at Advanced Therapies Week 2025 in Dallas. The nomination highlights their patented INTASYL technology, a siRNA gene silencing platform designed to enhance immune cells' cancer-fighting capabilities.
Recent clinical data from their Phase 1b study of INTASYL compound PH-762 showed promising results, with one cutaneous squamous cell carcinoma patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance). The award ceremony will take place January 20-23, 2025, featuring judges from H.C. Wainwright & Co., Gama Biosciences, and Propel Biosciences.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for developing therapeutics using INTASYL® siRNA gene silencing technology to enhance immune cells' cancer-fighting capabilities, will have CEO and Chairman Robert Bitterman present on Tuesday, December 10, 2024, at 12:00 pm EST. Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website.
Phio Pharmaceuticals (NASDAQ: PHIO) has completed enrollment for the second cohort in its PH-762 Phase 1b dose-escalating clinical trial and added a sixth clinical site in San Diego. New data from the trial shows promising results, with one patient achieving complete response (100% tumor clearance) and another achieving partial response (90% tumor clearance) in the second dose cohort. The study evaluates PH-762, an INTASYL compound that silences PD-1, in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q3 2024 financial results and provided updates on its Phase 1b clinical trial for PH-762. The trial's second cohort is fully enrolled, showing promising early results with one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in cutaneous squamous cell carcinoma patients. Financial highlights include cash position of $5.4 million as of September 30, 2024, reduced R&D expenses of $0.6 million (down 64% YoY), and a narrowed net loss of $1.5 million compared to $2.8 million in Q3 2023. The company raised approximately $2.6 million through warrant exercises in July 2024.
Phio Pharmaceuticals (NASDAQ: PHIO) announced new clinical data presentation from its ongoing Phase 1b trial at the 39th Annual SITC Meeting. The trial evaluates PH-762 through intratumoral injection in patients with various skin cancers. Results show the treatment has been well-tolerated with no adverse events across five patients in Cohorts 1 and 2.
Notable outcomes include one complete response (100% tumor clearance) and one partial response (90% tumor clearance) in patients with cutaneous squamous cell carcinoma in the second cohort. The trial, expected to complete enrollment by Q3 2025, demonstrates promising results in making immune cells more effective at killing cancer cells using INTASYL® siRNA technology.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, announces its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company, known for its INTASYL® siRNA gene silencing technology aimed at enhancing immune cells' cancer-fighting capabilities, will have CEO and Board Chairman Robert Bitterman present on Thursday, November 7 at 12:00 pm EST.
Stakeholders and investors are invited to attend this live virtual event, with a replay available on Renmark Financial Communications' website. The presentation focuses on Phio's innovative approach to creating new pathways towards a cancer-free future through their proprietary technology.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
